Provided by Tiger Trade Technology Pte. Ltd.

AbCellera Biologics

11.41
+0.24002.15%
Pre-market: 11.440.0300+0.26%09:13 EDT
Volume:3.73M
Turnover:42.48M
Market Cap:3.70B
PE:-20.91
High:11.69
Open:11.17
Low:10.90
Close:11.17
52wk High:12.58
52wk Low:2.75
Shares:324.00M
Float Shares:221.00M
Volume Ratio:0.99
T/O Rate:1.69%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5455
EPS(LYR):-0.4902
ROE:-17.30%
ROA:-10.39%
PB:4.13
PE(LYR):-23.28

Loading ...

Press Release: AbCellera Reports Q2 2026 Business Results

Dow Jones
·
Aug 06

Abcellera Biologics Inc Expected to Post a Loss of 14 Cents a Share - Earnings Preview

Reuters
·
Aug 04

Earning Preview: AbCellera Biologics Q2 revenue is expected to increase by 27.21%, and institutional views are cautiously positive

Earnings Agent
·
Jul 30

AbCellera Partners with Vertex to Develop Multispecific T-cell Engagers for Autoimmune Diseases, Other Conditions

Reuters
·
Jul 29

Abcellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions

THOMSON REUTERS
·
Jul 29

Abcellera Biologics - Vertex to Fund All R&D and Commercialize Antibodies from Collaboration

THOMSON REUTERS
·
Jul 29

Abcellera Biologics - Abccellera to Receive $28 Mln Upfront Plus Milestone Payments and Tiered Royalties

THOMSON REUTERS
·
Jul 29

Does AbCellera’s New Board Appointment Reframe Its Execution Story for Investors in ABCL?

Simply Wall St.
·
Jul 20

Analysts Offer Insights on Healthcare Companies: Insmed (INSM), AbCellera Biologics (ABCL) and DBV Technologies SA – American (DBVT)

TIPRANKS
·
Jul 17

Analysts Offer Insights on Healthcare Companies: Alumis Inc. (ALMS) and AbCellera Biologics (ABCL)

TIPRANKS
·
Jul 16

AbCellera Biologics call volume above normal and directionally bullish

TIPRANKS
·
Jul 10

Press Release: Abcellera to Report Second Quarter 2026 Financial Results on August 5, 2026

Dow Jones
·
Jul 08

Abcellera Schedules Q2 2026 Results, Earnings Call

Reuters
·
Jul 08

Abcellera Biologics Raised to Buy from Hold by Benchmark

Dow Jones
·
Jul 07

Benchmark Upgrades AbCellera Biologics to Buy From Hold, Price Target is $11

MT Newswires Live
·
Jul 07

Abcellera Biologics Inc : Benchmark Raises to Buy from Hold

THOMSON REUTERS
·
Jul 07

What AbCellera Biologics (ABCL)'s New Oncology Veteran Director Means For Shareholders

Simply Wall St.
·
Jul 07

Abcellera Files Form 3 as Director Lynn Seely Reports no Beneficial Ownership

Reuters
·
Jul 07

AbCellera Biologics Adds Independent Director to Board

TIPRANKS
·
Jul 07

AbCellera apponts Lynn Seely to board of directors

TIPRANKS
·
Jul 06